stockrowArcus Biosciences, Inc.
RCUS Healthcare Biotechnology
Arcus Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $247.0 million, down 4.26% from fiscal 2024.
- Revenue
- −65.4%
- EPS
- +21.3%
- Free cash flow
- +9.28%
- Total debt
- +4.08%
Quarter to September 2026, against a year earlier
Follow RCUS
Alert me
Arcus Biosciences, Inc. (RCUS) Shares outstanding
Arcus Biosciences, Inc.'s shares outstanding at the end of fiscal 2025 was $107.4M, up 19.2% from $90.1M in fiscal 2024. At the end of the quarter to 30 September 2026 it was $127.4M. Over the past ten years it has ranged from $864.0K (fiscal 2016) to $107.4M (fiscal 2025) — the current reading is the highest in ten years. Arcus Biosciences, Inc. ranks 104th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $107.4M | 19.20% |
| FY2024 | $90.1M | 21.76% |
| FY2023 | $74.0M | 2.78% |
| FY2022 | $72.0M | (2.70%) |
| FY2021 | $74.0M | 35.04% |
| FY2020 | $54.8M | 25.04% |
| FY2019 | $43.8M | 26.60% |
| FY2018 | $34.6M | 1,793.76% |
| FY2017 | $1.8M | 111.57% |
| FY2016 | $864.0K | — |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $127.4M | 1.03% |
| Jun 2026 | $126.1M | 0.56% |
| Mar 2026 | $125.4M | 16.76% |
| Dec 2025 | $107.4M | 0.85% |
| 35 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| RXRX Recursion Pharmaceuticals, Inc. compare | $543.0M |
| RCUS Arcus Biosciences, Inc. | $127.4M |
| NAMS NewAmsterdam Pharma Company N.V. compare | $124.1M |
| ZLAB Zai Lab Limited Unsponsored ADR compare | $111.7M |
| BEAM Beam Therapeutics Inc. compare | $104.7M |
| IDYA IDEAYA Biosciences, Inc. compare | $102.9M |
| XNCR Xencor, Inc. compare | $75.9M |
| PHVS Pharvaris N.V. compare | $68.1M |
| MBX MBX Biosciences, Inc. compare | $47.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on RCUS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement